Please login to the form below

Not currently logged in


This page shows the latest Breyanzi news and features for those working in and with pharma, biotech and healthcare.

BMS reports strong growth as its Q3 results beat predictions

BMS reports strong growth as its Q3 results beat predictions

up from $24m in Q2, while Breyanzi (lisocabtagene maraleucel), launched this year in lymphoma, had $30m in sales, up from $17m earlier in the year.

Latest news

More from news
Approximately 3 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...